Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5206672
Max Phase: Preclinical
Molecular Formula: C57H78N16O11S2Se
Molecular Weight: 1306.45
Associated Items:
ID: ALA5206672
Max Phase: Preclinical
Molecular Formula: C57H78N16O11S2Se
Molecular Weight: 1306.45
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)c2ccc(-n3[se]c4ccccc4c3=O)cc2)C(=O)N[C@@H](CCN)C(=N)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C57H78N16O11S2Se/c1-30(2)25-42(56(83)84)69-53(80)44-29-86-85-28-43(70-48(75)32-17-19-34(20-18-32)73-55(82)36-12-5-7-16-45(36)87-73)52(79)66-38(21-23-59)47(60)65-39(15-10-24-63-57(61)62)49(76)68-41(26-33-27-64-37-13-6-4-11-35(33)37)51(78)72-46(31(3)74)54(81)67-40(50(77)71-44)14-8-9-22-58/h4-7,11-13,16-20,27,30-31,38-44,46,64,74H,8-10,14-15,21-26,28-29,58-59H2,1-3H3,(H2,60,65)(H,66,79)(H,67,81)(H,68,76)(H,69,80)(H,70,75)(H,71,77)(H,72,78)(H,83,84)(H4,61,62,63)/t31-,38+,39+,40+,41+,42+,43+,44+,46+/m1/s1
Standard InChI Key: ILSQNUIYEZJOJC-ZOWDERHGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1306.45 | Molecular Weight (Monoisotopic): 1306.4643 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Liu J, Xu S, Huang C, Shen J, Yu S, Yu Y, Sun Q, Dai Q.. (2022) Synthesis and activity evaluation of selenazole-coupled CPI-1 irreversible bifunctional inhibitors for botulinum toxin A light chain., 73 [PMID:35914651] [10.1016/j.bmcl.2022.128913] |
Source(1):